Health Care/Hospital

Global Times: Small and mid-sized cities in China go through infection peak, bearing new hope for future

BEIJING, Feb. 1, 2023 /PRNewswire/ -- As media sources around the world have paid so much attention to infection surges in various metropolises or first-and-second-tier cities inChina and governments at all levels have attached great importance to anti-epidemic work in rural areas, a review on ho...

2023-02-01 22:45 2291

Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved

WUHAN, China, Feb. 1, 2023 /PRNewswire/ -- NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other mo...

2023-02-01 22:08 1738

Healint announces a collaboration with University of Toronto, Canada, to study the role of pollution on Migraine

PALO ALTO, Calif., Feb. 1, 2023 /PRNewswire/ -- Healint, the developer and owner of Migraine Buddy – the world's largest migraine tracking and research platform used by more than 3 million people and tens of thousands of migraine and pain clinics – andwww.weather-migraine.com

2023-02-01 22:00 1650

CBC Group Appoints Chief Operating Officer, Strengthening the Firm's Global Operational Capabilities

The former BlackRock and Goldman Sachs executive will oversee the firm's business management functions, including Finance, Human Resources, Legal & Compliance, Branding & Communications, and Technology SINGAPORE, Feb. 1, 2023 /PRNewswire/ -- Singapore-headquartered asset management firm, CBC Gro...

2023-02-01 20:18 2091

HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update

* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...

2023-02-01 20:00 1921

Global Times: Having weathered epidemic storms overseas, Chinese return to hometown for safe, joyous Spring Festival reunions

BEIJING, Jan. 31, 2023 /PRNewswire/ -- Red lanterns are once again hung in the contemporary houses that combine Chinese and Western elements in the famous hometown of overseas Chinese in East China'sFujian Province. For countless overseas Chinese, this year's Spring Festival provided an opportun...

2023-01-31 22:10 2339

CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer

SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...

2023-01-31 21:50 3123

Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away

BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...

2023-01-31 21:41 2274

Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection

* Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC * Lunit's AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health's portfolio of...

2023-01-31 21:05 2153

Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China

SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang...

2023-01-31 20:30 1792

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...

2023-01-31 20:25 3066

Singleron to present single cell sequencing solutions at the 36th Molecular Biology of Plants Conference

COLOGNE, Germany, Jan. 31, 2023 /PRNewswire/ -- Singleron Biotechnologies , a leader in single cell sequencing, will present at the upcoming 36th Molecular Biology of Plants 2023 (MBP2023) Conference of the Section Plant Physiology and Molecular Biology of the German Socie...

2023-01-31 16:00 2129

Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...

2023-01-31 09:24 1893

Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China

BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...

2023-01-30 23:00 2246

Health in Tech to Attend Health Care Administration Association (HCAA) Executive Forum 2023 as Corporate Sponsor

HCAA's Executive Forum 2023 is scheduled for February 20-22, 2023, at the Bellagio inLas Vegas. Be sure to stop by booth NL #9 to meet Health in Tech leadership. STUART, Fla., Jan. 30, 2023 /PRNewswire/ -- Health in Tech ("HIT", or "the Company"), an industry-leading Insurtech company that deliv...

2023-01-30 22:00 1648

Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases

SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...

2023-01-30 10:00 2172

WHO Goodwill Ambassador for Leprosy Elimination Has Audience with Pope Francis

Pope Supports Continued Efforts Against Leprosy, Reflects on Tragedy of War TOKYO, Jan. 27, 2023 /PRNewswire/ -- WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa had an audience with His Holiness Pope Francis at the Vatican onJanuary 26, 2023, during which he requested the Pope's su...

2023-01-27 22:00 3796

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...

2023-01-27 20:00 4069

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results

* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...

2023-01-27 14:52 3650

Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab

HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced the Hart-Scott-Rodino (HSR) Act filing has c...

2023-01-26 20:24 3652
1 ... 116117118119120121122 ... 278